

FORM P.T.O.-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
AMBIINC 008AAPPLICATION NO
10/001,322INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Komorowski et al.FILING DATE
October 31, 2001GROUP
1614

1651

RECEIVED
APR 24 2002
TECH CENTER 1600 2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
PP	1	Re. 33,988	07/07/92	Evans			
	2	4,954,492	09/04/90	Jensen			
	3	5,087,623	02/11/92	Boynton et al.			
	4	5,087,624	02/11/92	Boynton et al.			
	5	5,175,156	12/29/92	Boynton et al.			
	6	5,194,615	03/16/93	Jensen			
	7	5,543,405	08/06/96	Keown et al.			
PP	8	5,789,401	08/04/98	McCarty			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
PP	9	WO 96/35421	11/14/96	PCT				

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

EXAMINER INITIAL		
PP	10.	Anderson (1986) Chromium metabolism and its role in disease processes in man. Clinical Physiology and Biochemistry. Abstract in 1 page.
Y	11.	Atkinson (2000) Clinical implications for CLA in the treatment of obesity. Richard L. Atkinson, M.D., Professor of Medicine and Nutritional Sciences, University of Wisconsin, Madison, WI. 1 page.
	12.	Bauer et al. (1998) Coated pharmaceutical dosage forms: Fundamentals, manufacturing techniques, biopharmaceutical aspects, test methods and raw materials. CRC Press, Washington, DC. 81-85
	13.	Boyle, Jr. et al. (1977) Chromium depletion in the pathogenesis of diabetes and atherosclerosis. 1977) Southern Medical Journal. 70(12):1449-1453.
	14.	Carstensen, J.T. (1993) Pharmaceutical principles of solid dosage forms. Technomic Publishing Co., Inc., Lancaster, PA. 228-230.
	15.	Cefalu et al. (1999) Effect of chromium picolinate on insulin sensitivity in vivo. J Trace Elem Exp Med. 12:71-83.
	16.	Kaats et al. (1998) A randomized, double-masked, placebo-controlled study of the effects of chromium picolinate supplementation on body composition: a replication and extension of a previous study. Current Therapeutic Research. 59(6):379-388.
	17.	Kamath et al. (1997) Absorption, retention and urinary excretion of chromium-51 in rats pretreated with indomethacin and dosed with dimethylprostaglandin E ₂ , misoprostol or prostacyclin ^{1,2,3} . J Nutr. 127:478-482.
	18.	Keegan et al. (1999) Effects of diabetes and treatment with the antioxidant α -lipoic acid on endothelial and neurogenic responses of corpus cavernosum in rats. Diabetologia. 42:343-350.
	19.	Khamaisi et al. (1999) Lipoic acid acutely induces hypoglycemia in fasting nondiabetic and diabetic rats. Metabolism. 48(4):504-510.
	20.	Kishi et al. (1999) α -Lipoic acid. effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy. Diabetes. 48:2045-2051
PP	21.	Nagamatsu et al. (1995) Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care. 18(8) 1160-1167.

EXAMINER

DATE CONSIDERED

9/18/02

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

TECH CENTER 1600 2900

RECEIVED
SHEET 2 OF 2
APR 2 8 2001

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO AMBIINC 008A	APPLICATION NO. 10/001,322
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Komorowski et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE October 31, 2001	GROUP 1614 1651

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
PP	22. Obrosova et al. (1998) Diabetes-induced change in lens antioxidant status, glucose utilization and energy metabolism: effect of DL- α -lipoic acid. <i>Diabetologia</i> . 41:1442-1450.
↑	23. Park et al. (1999) Conjugated Linoleic Acid (CLA). Food Research Institute. pp 48-56.
	24. Pi-Sunyer et al. (1984) Chromium. Nutrition Reviews' Present Knowledge in Nutrition, Fifth Edition. The Nutrition Foundation, Inc., Washington, D C 571-577.
	25. Reljanovic et al. (1999) Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (α -lipoic acid). A two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). <i>Free Rad Res</i> . 31:171-179
	26. Ruhnaut et al. (1999) Effects of 3-week oral treatment with the antioxidant thioctic acid α -lipoic acid) in symptomatic diabetic polyneuropathy. <i>Diabet Med</i> . 16:1040-1043.
	27. Singh et al. (1986) Pharmacology of an extract of salai guggal ex- <i>Boswellia serrata</i> , a new non-steroidal anti-inflammatory agent. <i>Agents and Actions</i> . 18:407-412.
	28. Ziegler et al. (1995) Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant α -lipoic acid. <i>Diabetologia</i> . 38:1425-1433
	29. Ziegler et al. (1999) Treatment of symptomatic diabetic polyneuropathy with the antioxidant α -lipoic acid. <i>Diabetes Care</i> . 22(8):1296-1301.
↓	30. Ziegler et al. (1999) α -Lipoic acid in the treatment of diabetic polyneuropathy in Germany: Current evidence from clinical trials. <i>Exp Clin Endocrinol Diabetes</i> . 107:421-430.
PP	31. Recommended Daily Allowances, Ninth Revised Edition, 1980. National Academy of Sciences, Washington, D C.

S:\DOCS\MKD\MKD-2694.DOC\041602

EXAMINER <i>Charles A. Felt</i>	DATE CONSIDERED 9/18/02
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	